BioLegend

Executive Summary

BioLegend is a leading global developer and manufacturer of high-quality antibodies, reagents, assays, and research tools for the biomedical community. Founded in 2002 and headquartered in San Diego, the company serves academic, biopharmaceutical, and diagnostic laboratories worldwide. Its extensive product portfolio spans immunology, neuroscience, cancer, and stem cell biology, positioning it as a key supplier in the life sciences tools market. As a privately held company, BioLegend has built a strong reputation for quality and innovation, with a broad customer base and established distribution channels. The company benefits from secular growth in biomedical research spending, particularly in immuno-oncology and cell therapy, where its reagents are essential for discovery and development. While financial details are not publicly disclosed, BioLegend's consistent market presence and broad product adoption suggest a stable and growing revenue base.

Upcoming Catalysts (preview)

• Q2 2026Launch of next-generation flow cytometry reagents70% success
• H2 2026Strategic partnership with a major biopharma for immuno-oncology assays60% success
• Q3 2026Expansion of custom antibody and service business into Asia-Pacific80% success